WuXi AppTec Co., Ltd. (2359.HK)

35.550 -0.750 (-2.07%) At close: 04:08PM HKT

WuXi AppTec Co., Ltd.

288 Fute Zhong Road
Waigaoqiao Free Trade Zone
Shanghai 200131
China
86 21 5046 1111
https://www.wuxiapptec.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 41,116

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ge Li Ph.D.	Co-Founder, Chairman, President & CEO	45.23M	N/A	1967
Dr. Minzhang Chen Ph.D.	Co-CEO & Executive Director	11.78M	N/A	1969
Dr. Qing Yang Ph.D.	Co-CEO & Executive Director	8.18M	N/A	1969
Dr. Edward Hu M.B.A.	Vice Chairman, Global Chief Investment Officer, CEO of WuXi ATU & Head of DDSU	9.02M	N/A	1962
Ms. Ming Shi	Senior VP & CFO	N/A	N/A	1974
Mr. Zhaohui Zhang	COO of China, Executive VP & Executive Director	7.59M	N/A	1969
Mr. Yuanzhou Zhang	Joint Company Secretary	N/A	N/A	1988
Mr. Ruijia Tang	IR Director	N/A	N/A	N/A
Dr. Jingchao Dong Ph.D.	Senior VP & Head of RCS	N/A	N/A	N/A
Mr. Tao Guo Ph.D.	Senior VP and Head of RCS BD&IPM	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical testing services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

Corporate governance

WuXi AppTec Co., Ltd.’s ISS governance QualityScore as of 1 May 2024 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 9; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.